Caricamento...
The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with metastatic ALK(+) non–small‐cell lung cancer who have progressed on or are intolerant to crizotinib. A clinical study was conducted to asses...
Salvato in:
| Pubblicato in: | Clin Pharmacol Drug Dev |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767012/ https://ncbi.nlm.nih.gov/pubmed/30570839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.641 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|